Autologous cultured chondrocytes - Vericel

Drug Profile

Autologous cultured chondrocytes - Vericel

Alternative Names: Articel; Cartilage replacement - Sanofi; MACI; MACI Implant; Matrix applied characterised autologous cultured chondrocytes - Genzyme; Matrix-induced autologous chondrocyte implant

Latest Information Update: 25 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Verigen AG
  • Developer Vericel Corporation
  • Class Cell therapies
  • Mechanism of Action Cartilage replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Knee injuries
  • Phase II Osteonecrosis

Most Recent Events

  • 10 May 2017 Autologous cultured chondrocytes - Vericel licensed to Innovative Cellular Therapeutics in China, South Korea, Singapore, and other South-East Asia countries
  • 01 Feb 2017 Launched for Knee injuries in USA (Parenteral)
  • 20 Dec 2016 Planned Prescription Drug User Fee Act (PDUFA) date for Knee injuries in USA (Parenteral) is 2017-01-03
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top